ストックスクリーナーアプリを入手
2.02
1.94%
-0.04
前日終値:
$2.06
開ける：
$2.03
24時間の取引高:
21,090
Relative Volume:
0.24
時価総額：
$149.95M
収益：
-
当期純損益:
$-4.67M
株価収益率:
-31.81
EPS:
-0.0635
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-0.49%
1か月 パフォーマンス:
-9.01%
6か月 パフォーマンス:
+30.32%
1年 パフォーマンス:
-94.90%
1日の値動き範囲:
$2.0001
$2.10
1週間の範囲:
$2.00
$2.19
52週間の値動き範囲:
$1.43
$67.00
Jyong Biotech Ltd Stock (MENS) Company Profile
Compare MENS vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MENS
Jyong Biotech Ltd
|
2.02 | 151.44M | 0 | -4.67M | 0 | -0.0635 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Jyong Biotech Ltd (MENS) 最新ニュース
Jyong Biotech Highlights Multi-Billion Dollar Global BPH Market Opportunity and Reaffirms Strategic Focus on Global Licensing Partnerships - Macau Business
Jyong Biotech Ltd (MENS) Institutional Confidence - TradingKey
Jyong Biotech Ltd (MENS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Jyong Biotech Ltd (MENS) Income Statement - TradingKey
Jyong Biotech Ltd (MENS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
MENS|Jyong Biotech Ltd|Price:2.360|Chg%:-0.350 - TradingKey
Jyong Biotech Ltd (MENS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Jyong Biotech Ltd (MENS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Jyong Biotech Ltd (MENS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Jyong Biotech Ltd (MENS) Balance Sheet - TradingKey
Jyong Biotech Ltd (MENS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Jyong Biotech pursues global licensing partnerships for BPH drug By Investing.com - Investing.com Nigeria
Jyong Biotech targets $22B global BPH market wi... - Pluang
Jyong Biotech pursues global licensing partnerships for BPH drug - Investing.com
Jyong Biotech Ltd. Reaffirms Global Licensing Strategy for Botanical BPH Drug Candidate Botreso - Quiver Quantitative
Benign prostatic hyperplasia patients projected to reach 150M-156M by 2035 - Stock Titan
Jyong Biotech (MENS) Gains 3.88% as Positive Momentum Targets Key ResistanceHead and Shoulders - dars.gov.et
Jyong Biotech Ltd. (NASDAQ:MENS) Short Interest Down 36.2% in June - MarketBeat
Jyong Biotech (MENS) Dips 1.3% as Stock Approaches Key Support at $2.16Bollinger Squeeze - dars.gov.et
Jyong Biotech Showcases Botanical Drug Portfolio at BIO 2026 International Convention - Macau Business
Jyong Biotech presents drug candidate at BIO 2026 convention By Investing.com - Investing.com Nigeria
Jyong Biotech presents drug candidate at BIO 2026 convention - Investing.com
Jyong Biotech advances botanical drug Botreso® at BIO 2026, targeting global licensing for BPH treatment. - Pluang
Jyong Biotech (MENS) Retreats Over 5% as Key Support Test LoomsForce Index - dars.gov.et
Price to sales forward of Jyong Biotech Ltd. – NASDAQ:MENS - TradingView
Enterprise value to EBIT forward of Jyong Biotech Ltd. – NASDAQ:MENS - TradingView
Enterprise value to EBITDA forward of Jyong Biotech Ltd. – NASDAQ:MENS - TradingView
Price to book forward of Jyong Biotech Ltd. – NASDAQ:MENS - TradingView
Jyong Biotech Ltd. (MENS) Modest Gain Amidst Tight Trading RangeDefined Outcome ETF - DonanımHaber
Jyong Biotech Ltd (MENS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Number of shareholders of Jyong Biotech Ltd. – NASDAQ:MENS - TradingView
Jyong Biotech Ltd (MENS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Certain Ordinary Shares of Jyong Biotech Ltd. are subject to a Lock-Up Agreement Ending on 16-JUN-2026. - marketscreener.com
JYONG BIOTECH LTD (MENS) Stock Chart - ChartMill
Jyong Biotech CEO Outlines FDA Pathway and Global Strategy in PharmaBoardroom Live Interview - digitalmore.co
Jyong Biotech outlines FDA approval path for botanical drug Botreso® targeting benign prostatic hyperplasia. - Pluang
Jyong Biotech (MENS) Remains Range-Bound as Price Consolidates Near SupportPut Flow Alert - The Legal Advocate
MENSJyong Biotech Ltd Stock Price and Quote - Finviz
Jyong Biotech Ltd. (MENS) Rises 2.36% as Stock Approaches Key ResistanceEarnings Quality Factor - dars.gov.et
Jyong Biotech Ltd. (MENS) Surges 3.37% as Buyers Defend Key Support LevelTake Profit Levels - The Legal Advocate
Jyong Biotech Ltd. (MENS) Shows Resilience: Uptick from Key Support ZoneImbalance Zone - The Legal Advocate
Jyong Biotech Ltd. (MENS) Gains 3.37% as Technical Support Holds, Resistance in FocusIV Rank - Newser
Jyong Biotech Ltd. (MENS) Stabilizes Near Key Support After Modest UptickIchimoku TK Cross - Newser
MENS Stock Price, Quote & Chart | JYONG BIOTECH LTD (NASDAQ:MENS) - ChartMill
Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025 - marketscreener.com
Jyong Biotech (NASDAQ: MENS) flags Botreso FDA hurdles and $19.4M judgment - Stock Titan
Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year Ended December 31, 2025 - Quiver Quantitative
DXS INTERNATIONAL PLC (AQSE: DXSP): Issue of New Shares and Notification of Director / PDMR Dealings - Weekly Voice
Jyong Biotech Ltd (MENS) 財務データ
収益
当期純利益
現金流量
EPS
0.52%
0.07%
大文字化:
|
ボリューム (24 時間):